☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Everest Medicines
Everest Medicines Signed a MoU with Shanghai Pharma Subsidiary to Advance the Commercialization of Xerava (eravacycline) in Mainla...
April 19, 2023
Singapore HSA Accepts NDA of Everest Medicines’ Nefecon for the Treatment of Primary IgA Nephropathy
April 6, 2023
Everest Medicines’ Xerava (eravacycline) Receives NMPA’s Approval for Complicated Intra-Abdominal Infections in Adult Patients
March 17, 2023
Everest Medicines and Calliditas Receives Priority Review for Nefecon in IgA Nephropathy for China
January 2, 2023
Everest Medicines Licensing Partner Pfizer Reports the US FDA and EMA’s Acceptance of NDA and MAA for Etrasimod in Ulcerative Coli...
December 22, 2022
Everest Medicines Receives the NMPA’s IND Approval for EVER001 to Treat Renal Diseases
September 26, 2022
Load more...
Back to Home